Overview
The Health Ministry has widened the scope of Schedule H2 from a short list of brands to entire therapeutic classes. The move shifts regulation from a revenue‑based approach to a risk‑based one, aiming to curb counterfeit medicines and improve drug quality.
Key Developments
- All drugs in a therapeutic class must now carry a QR code containing product identifier, licence number, batch number and other details.
- The system will help trace defective batches and limit the flow of fake antimicrobials, opioids and psychotropic drugs.
- The Jan Vishwas Act 2026 now treats only substantial non‑compliance as enforceable, reducing discretionary penalties.
- Implementation will require a state‑managed, real‑time database and interoperable scanning infrastructure across all states.
- Compliance costs may strain MSME manufacturers.
Important Facts
India records one of the highest global rates of antimicrobial resistance. Sub‑standard antimicrobials can cause sub‑therapeutic dosing, encouraging resistant strains. The Narcotics Control Bureau has warned that medicinal opioids and psychotropic substances could leak into illicit markets.
International regulators such as the U.S. FDA and the European Medicines Agency have repeatedly raised concerns about Indian drug quality, especially after incidents involving contaminated cough syrups. The U.S. Trade Representative also lists India as a major source of counterfeit medicines seized at the U.S. border.
Exam Relevance
Understanding this policy helps answer questions in GS4 (Health) on drug safety, GS2 (Polity) on regulatory reforms, and GS3 (Economy) on the impact on MSMEs. The shift to risk‑based regulation illustrates how governance can address public‑health challenges while balancing industry concerns.
Way Forward
- Build a robust, centrally managed digital platform that allows pharmacists and regulators to verify QR codes instantly.
- Promote a habit among pharmacists and consumers to scan codes before sale.
- Provide technical and financial support to MSME manufacturers for upgrading packaging and IT systems.
- Establish a secure digital governance layer to protect sensitive prescription data on controlled substances.
- Continuously monitor enforcement outcomes to ensure the framework improves India’s reputation as a reliable pharmaceutical hub.